123 related articles for article (PubMed ID: 15014015)
1. A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Hammond LA; Eckardt JR; Kuhn JG; Gerson SL; Johnson T; Smith L; Drengler RL; Campbell E; Weiss GR; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2004 Mar; 10(5):1645-56. PubMed ID: 15014015
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
Schold SC; Kuhn JG; Chang SM; Bosik ME; Robins HI; Mehta MP; Spence AM; Fulton D; Fink KL; Prados MD
Neuro Oncol; 2000 Jan; 2(1):34-9. PubMed ID: 11302252
[TBL] [Abstract][Full Text] [Related]
3. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Plowman J; Waud WR; Koutsoukos AD; Rubinstein LV; Moore TD; Grever MR
Cancer Res; 1994 Jul; 54(14):3793-9. PubMed ID: 8033099
[TBL] [Abstract][Full Text] [Related]
4. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
[TBL] [Abstract][Full Text] [Related]
5. Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.
Panella TJ; Smith DC; Schold SC; Rogers MP; Winer EP; Fine RL; Crawford J; Herndon JE; Trump DL
Cancer Res; 1992 May; 52(9):2456-9. PubMed ID: 1533174
[TBL] [Abstract][Full Text] [Related]
6. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Mitchell RB; Dolan ME
Cancer Chemother Pharmacol; 1993; 32(1):59-63. PubMed ID: 8462125
[TBL] [Abstract][Full Text] [Related]
7. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
Tolcher AW; Gerson SL; Denis L; Geyer C; Hammond LA; Patnaik A; Goetz AD; Schwartz G; Edwards T; Reyderman L; Statkevich P; Cutler DL; Rowinsky EK
Br J Cancer; 2003 Apr; 88(7):1004-11. PubMed ID: 12671695
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
9. Sequential therapy with dacarbazine and carmustine: a phase I study.
Mitchell RB; Dolan ME; Janisch L; Vogelzang NJ; Ratain MJ; Schilsky RL
Cancer Chemother Pharmacol; 1994; 34(6):509-14. PubMed ID: 7923562
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Hammond LA; Eckardt JR; Baker SD; Eckhardt SG; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss GR; Rinaldi DA; Von Hoff DD; Rowinsky EK
J Clin Oncol; 1999 Aug; 17(8):2604-13. PubMed ID: 10561328
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Raizer JJ; Malkin MG; Kleber M; Abrey LE
Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
[TBL] [Abstract][Full Text] [Related]
12. Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase.
Smith DC; Gerson SL; Liu L; Donnelly S; Day R; Trump DL; Kirkwood JM
Clin Cancer Res; 1996 Jul; 2(7):1129-34. PubMed ID: 9816278
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.
Wedge SR; Porteus JK; May BL; Newlands ES
Br J Cancer; 1996 Feb; 73(4):482-90. PubMed ID: 8595163
[TBL] [Abstract][Full Text] [Related]
14. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM
Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959
[TBL] [Abstract][Full Text] [Related]
16. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
Rudek MA; Donehower RC; Statkevich P; Batra VK; Cutler DL; Baker SD
Pharmacotherapy; 2004 Jan; 24(1):16-25. PubMed ID: 14740784
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Prados MD; Yung WK; Fine HA; Greenberg HS; Junck L; Chang SM; Nicholas MK; Robins HI; Mehta MP; Fink KL; Jaeckle KA; Kuhn J; Hess KR; Schold SC;
Neuro Oncol; 2004 Jan; 6(1):33-7. PubMed ID: 14769138
[TBL] [Abstract][Full Text] [Related]
19. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Kurpad SN; Dolan ME; McLendon RE; Archer GE; Moschel RC; Pegg AE; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1997; 39(4):307-16. PubMed ID: 9025771
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK
Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
